pfizer

"With new cases in children in the U.S. continuing to be at a high level, this submission is an important step in our ongoing effort against #COVID19," the pharmaceutical giant said.

What happened? Here are six lessons learned from Israel's experience — and one looming question for the future of the pandemic.

The challenge of refrigerating COVID-19 vaccines is acute in sub-Saharan Africa, where only 28% of health care facilities have reliable power. One solution? A new kind of freezer powered by the sun.

On the first European trip of his presidency, Biden will announce a major U.S. contribution to the global vaccine effort — part of an effort to end COVID-19 "everywhere."

The agreement provides a significant boost to the European Union's goal of getting 70% of adults vaccinated. Currently, around a quarter of the bloc's population is vaccinated.

One of the hottest areas of research right now: studies to determine how well current vaccines work against emerging coronavirus "variants of concern."

Pfizer and Moderna each agreed to supply 100 million doses of COVID-19 vaccine to the U.S. by the end of March. With just under three weeks left, both companies have their work cut out for them.

Many of the coronavirus vaccines like it cold. Really cold. Sub-zero cold. Why is this the case? And how is the world handling this frigid requirement?

Israel paid a premium, locked in an early supply of Pfizer-BioNTech vaccines and agreed to share data from Israel's centralized trove of medical statistics. Privacy advocates have some misgivings.

The two companies making COVID-19 vaccines each promised to deliver 100 million doses to the federal government by the end of March. So far, they appear to be running behind.